In 2012, GSK pled guilty to the unlawful promotion of certain prescription medications, including Zofran, among other illegal activities, including failure to report certain safety information and false price reporting. The company was required to pay $3 billion in both criminal and civil damages. GSK paid over $1 billion in regards to the off-labeled promotion and kickbacks for Zofran and other medications.